The PCa IME impacts anti-tumour immune responses via the upregulation of immune checkpoint proteins (e.g., PD-L1) to inhibit T-cell activity [118,119], increasing the expression of IL-8 [117] and the secretion of growth factors, facilitating angiogenesis and matrix remodelling from TAMs, and promoting tumour growth and immunosuppression to drive tumour progression [61]. The gene discussed is CD274; the disease is neoplasm.